%0 Journal Article
%T Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
%A Camilla Corte
%A Georgia Myers
%A Kerrie Hudson
%A Li Li
%A Mark Gilman
%A Richard Littlewood
%A Tara Lumley
%J Archive of "Patient preference and adherence".
%D 2018
%R 10.2147/PPA.S180641
%X Integrated treatment for opioid use disorder (OUD) includes opioid agonist therapy (OAT) such as methadone and buprenorphine with well-evidenced benefits. Treatment with typical existing oral medications is associated with burdens and limits to successful outcomes (frequent dosing, attendance for collection/consumption, difficulty in achieving optimal dosing, misuse, diversion, accidental exposure, and stigma from the treatment process). Novel medications include injected depot formulations with less frequent administration, providing consistent drug levels after dosing. This survey assesses the opinion of those with OUD treatment services lived experience to inform future medication choices
%K opioid agonist therapy
%K lived experience
%K innovation
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188959/